Literature DB >> 16903003

Multivariate time-to-event analysis of multiple adverse events of drugs in integrated analyses.

Achim Güttner1, Jürgen Kübler, Iris Pigeot.   

Abstract

In each clinical trial the statistical evaluation of adverse events (AEs) is a major part of standard safety analyses. However, the analyses of AEs usually lack from adequately accounting for the occurrence of multiple, different AEs. Furthermore, predictive variables other than treatment such as age, sex and concomitant medication are often ignored. These issues can be addressed by the Cox regression as introduced by Andersen and Gill and Wei et al. A further issue arises from the fact that an ordered programme of studies is conducted during clinical testing of pharmaceutical drugs. In this paper, we therefore discuss a stratified multivariate Cox regression model that can be used in integrated summaries of safety. We derive partial maximum likelihood estimators of the model parameters which can be shown to be consistent and asymptotically normally distributed. Mainly based on a sandwich estimator of their covariance matrix several test statistics are proposed that can be used to test various null hypotheses on the underlying parameters. Their asymptotic null distributions are given. The benefit of this survival time approach for analysing AEs is illustrated by evaluating symptoms of common cold from the database of a clinical development project. Copyright (c) 2006 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2007        PMID: 16903003     DOI: 10.1002/sim.2637

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  1 in total

1.  On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.

Authors:  Steffen Unkel; Marjan Amiri; Norbert Benda; Jan Beyersmann; Dietrich Knoerzer; Katrin Kupas; Frank Langer; Friedhelm Leverkus; Anja Loos; Claudia Ose; Tanja Proctor; Claudia Schmoor; Carsten Schwenke; Guido Skipka; Kristina Unnebrink; Florian Voss; Tim Friede
Journal:  Pharm Stat       Date:  2018-11-20       Impact factor: 1.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.